Features of aggressive breast cancer

Breast

Volumn 24, Issue 5, 2015, Pages 594-600

  Arpino, Grazia ^a   Milano, Monica ^a   De Placido, Sabino ^a  

^a UNIVERSITY OF NAPLES FEDERICO II   (Italy)

Author keywords

Aggressive breast cancer; Biological features; Breast cancer; Clinical features; Metastatic breast cancer; Prognostic factors

Indexed keywords

ARTICLE; BRAIN METASTASIS; BREAST METASTASIS; CANCER GRADING; CANCER PROGNOSIS; CANCER RECURRENCE; CIRCULATING TUMOR CELL; CLINICAL FEATURE; DISEASE FREE INTERVAL; HISTOPATHOLOGY; HUMAN; PRIORITY JOURNAL; SYSTEMATIC REVIEW; TRIPLE NEGATIVE BREAST CANCER; TUMOR VOLUME; VISCERAL METASTASIS; ABDOMINAL TUMOR; BRAIN TUMOR; DISEASE FREE SURVIVAL; FEMALE; PATHOLOGY; SECONDARY; TUMOR EMBOLISM;

ABDOMINAL NEOPLASMS; BRAIN NEOPLASMS; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; NEOPLASM GRADING; NEOPLASTIC CELLS, CIRCULATING; TRIPLE NEGATIVE BREAST NEOPLASMS; TUMOR BURDEN;

EID: 84952638993     PISSN: 09609776     EISSN: 15323080     Source Type: Journal    
DOI: 10.1016/j.breast.2015.06.001     Document Type: Article

References (64)

1. Jemal A., Bray F., Center M.M., Ferlay J., Ward E., Forman D. Global cancer statistics. CA Cancer J Clin 2011, 61:69-90.
2. Siegel R., Ma J., Zou Z., Jemal A. Cancer statistics, 2014. CA Cancer J Clin 2014, 64:9-29.
3. Ferlay J., Steliarova-Foucher E., Lortet-Tieulent J., Rosso S., Coebergh J.W., Comber H., et al. Cancer incidence and mortality patterns in Europe: estimates for 40 countries in 2012. Eur J Cancer 2013, 49:1374-1403.
4. Howlader N, Noone AM, Krapcho M, Garshell J, Miller D, Altekruse SF, et al. SEER Cancer Statistics review, 1975-2011. Bethesda, MD: National Cancer Institute. Available at: [accessed 01.09.2014]. http://Seer.cancer.gov/csr/1975_2011/.
5. Colzani E., Johansson A.L., Liljegren A., Foukakis T., Clements M., Adolfsson J., et al. Time-dependent risk of developing distant metastasis in breast cancer patients according to treatment, age and tumour characteristics. Br J Cancer 2014, 110:1378-1384.
6. Koboldt D.C., Fulton R.S., McLellan M.D., Schmidt H., Kalicki-Veizer J., McMichael J.F., et al. Comprehensive molecular portraits of human breast tumours. Nature 2012, 490:61-70. for The Cancer Genome Atlas Network.
7. Liedtke C., Mazouni C., Hess K.R., Andre F., Tordai A., Mejia J.A., et al. Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer. J Clin Oncol 2008, 26:1275-1281.
8. Rouzier R., Perou C.M., Symmans W.F., Ibrahim N., Cristofanilli M., Anderson K., et al. Breast cancer molecular subtypes respond differently to preoperative chemotherapy. Clin Cancer Res 2005, 11:5678-5685.
9. Esserman L.J., Berry D.A., DeMichele A., Carey L., Davis S.E., Buxton M., et al. Pathologic complete response predicts recurrence-free survival more effectively by cancer subset: results from the I-SPY 1 TRIAL-CALGB 150007/150012, ACRIN 6657. J Clin Oncol 2012, 30:3242-3249.
10. Cianfrocca M., Goldstein L.J. Prognostic and predictive factors in early-stage breast cancer. Oncologist 2004, 9:606-616.
11. Carter C.L., Allen C., Henson D.E. Relation of tumor size, lymph node status, and survival in 24,740 breast cancer cases. Cancer 1989, 63:181-187.
12. Brufsky A.M., Hurvitz S., Perez E., Swamy R., Valero V., O'Neill V., et al. RIBBON-2: a randomized, double-blind, placebo-controlled, phase III trial evaluating the efficacy and safety of bevacizumab in combination with chemotherapy for second-line treatment of human epidermal growth factor receptor 2-negative metastatic breast cancer. J Clin Oncol 2011, 29:4286-4293.
13. Lang I., Brodowicz T., Ryvo L., Kahan Z., Greil R., Beslija S., et al. Bevacizumab plus paclitaxel versus bevacizumab plus capecitabine as first-line treatment for HER2-negative metastatic breast cancer: interim efficacy results of the randomised, open-label, non-inferiority, phase 3 TURANDOT trial. Lancet Oncol 2013, 14:125-133.
14. Robert N.J., Dieras V., Glaspy J., Brufsky A.M., Bondarenko I., Lipatov O.N., et al. RIBBON-1: randomized, double-blind, placebo-controlled, phase III trial of chemotherapy with or without bevacizumab for first-line treatment of human epidermal growth factor receptor 2-negative, locally recurrent or metastatic breast cancer. J Clin Oncol 2011, 29:1252-1260.
15. Kim H., Choi D.H., Park W., Huh S.J., Nam S.J., Lee J.E., et al. Prognostic factors for survivals from first relapse in breast cancer patients: analysis of deceased patients. Radiat Oncol J 2013, 31:222-227.
16. Staudacher L., Cottu P.H., Dieras V., Vincent-Salomon A., Guilhaume M.N., Escalup L., et al. Platinum-based chemotherapy in metastatic triple-negative breast cancer: the Institut Curie experience. Ann Oncol 2011, 22:848-856.
17. Dafni U., Grimani I., Xyrafas A., Eleftheraki A.G., Fountzilas G. Fifteen-year trends in metastatic breast cancer survival in Greece. Breast Cancer Res Treat 2010, 119:621-631.
18. Leonard R.C., Rodger A., Dixon J.M. ABC of breast diseases. Metastatic breast cancer. BMJ 1994, 309:1501-1504.
19. Chang J., Clark G.M., Allred D.C., Mohsin S., Chamness G., Elledge R.M. Survival of patients with metastatic breast carcinoma: importance of prognostic markers of the primary tumor. Cancer 2003, 97:545-553.
20. Gennari A., Conte P., Rosso R., Orlandini C., Bruzzi P. Survival of metastatic breast carcinoma patients over a 20-year period: a retrospective analysis based on individual patient data from six consecutive studies. Cancer 2005, 104:1742-1750.
21. Sledge G.W., Neuberg D., Bernardo P., Ingle J.N., Martino S., Rowinsky E.K., et al. Phase III trial of doxorubicin, paclitaxel, and the combination of doxorubicin and paclitaxel as front-line chemotherapy for metastatic breast cancer: an Intergroup trial (E1193). J Clin Oncol 2003, 21:588-592.
22. Palmieri D., Smith Q.R., Lockman P.R., Bronder J., Gril B., Chambers A.F., et al. Brain metastases of breast cancer. Breast Dis 2006-2007, 26:139-147.
23. Tsukada Y., Fouad A., Pickren J.W., Lane W.W. Central nervous system metastasis from breast carcinoma. Autopsy study. Cancer 1983, 52:2349-2354.
24. Kennecke H., Yerushalmi R., Woods R., Cheang M.C., Voduc D., Speers C.H., et al. Metastatic behavior of breast cancer subtypes. J Clin Oncol 2010, 28:3271-3277.
25. Jung S.Y., Rosenzweig M., Sereika S.M., Linkov F., Brufsky A., Weissfeld J.L. Factors associated with mortality after breast cancer metastasis. Cancer Causes Control 2012, 23:103-112.
26. Largillier R., Ferrero J.M., Doyen J., Barriere J., Namer M., Mari V., et al. Prognostic factors in 1,038 women with metastatic breast cancer. Ann Oncol 2008, 19:2012-2019.
27. Pierga J.Y., Robain M., Jouve M., Asselain B., Dieras V., Beuzeboc P., et al. Response to chemotherapy is a major parameter-influencing long-term survival of metastatic breast cancer patients. Ann Oncol 2001, 12:231-237.
28. Fountzilas G., Dafni U., Dimopoulos M.A., Koutras A., Skarlos D., Papakostas P., et al. A randomized phase III study comparing three anthracycline-free taxane-based regimens, as first line chemotherapy, in metastatic breast cancer: a Hellenic Cooperative Oncology Group study. Breast Cancer Res Treat 2009, 115:87-99.
29. Slamon D.J., Leyland-Jones B., Shak S., Fuchs H., Paton V., Bajamonde A., et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 2001, 344:783-792.
30. Sparano J.A., Vrdoljak E., Rixe O., Xu B., Manikhas A., Medina C., et al. Randomized phase III trial of ixabepilone plus capecitabine versus capecitabine in patients with metastatic breast cancer previously treated with an anthracycline and a taxane. J Clin Oncol 2010, 28:3256-3263.
31. Insa A., Lluch A., Prosper F., Marugan I., Martinez-Agullo A., Garcia-Conde J. Prognostic factors predicting survival from first recurrence in patients with metastatic breast cancer: analysis of 439 patients. Breast Cancer Res Treat 1999, 56:67-78.
32. Coleman R.E., Smith P., Rubens R.D. Clinical course and prognostic factors following bone recurrence from breast cancer. Br J Cancer 1998, 77:336-340.
33. Yamamoto N., Watanabe T., Katsumata N., Omuro Y., Ando M., Fukuda H., et al. Construction and validation of a practical prognostic index for patients with metastatic breast cancer. J Clin Oncol 1998, 16:2401-2408.
34. O'Shaughnessy J., Gradishar W.J., Bhar P., Iglesias J. Nab-paclitaxel for first-line treatment of patients with metastatic breast cancer and poor prognostic factors: a retrospective analysis. Breast Cancer Res Treat 2013, 138:829-837.
35. Carey L.A., Perou C.M., Livasy C.A., Dressler L.G., Cowan D., Conway K., et al. Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study. JAMA 2006, 295:2492-2502.
36. Clark G.M., Osborne C.K., McGuire W.L. Correlations between estrogen receptor, progesterone receptor, and patient characteristics in human breast cancer. J Clin Oncol 1984, 2:1102-1109.
37. Gluck S., de Snoo F., Peeters J., Stork-Sloots L., Somlo G. Molecular subtyping of early-stage breast cancer identifies a group of patients who do not benefit from neoadjuvant chemotherapy. Breast Cancer Res Treat 2013, 139:759-767.
38. Bauer K.R., Brown M., Cress R.D., Parise C.A., Caggiano V. Descriptive analysis of estrogen receptor (ER)-negative, progesterone receptor (PR)-negative, and HER2-negative invasive breast cancer, the so-called triple-negative phenotype: a population-based study from the California Cancer Registry. Cancer 2007, 109:1721-1728.
39. Perou C.M., Sorlie T., Eisen M.B., van de Rijn M., Jeffrey S.S., Rees C.A., et al. Molecular portraits of human breast tumours. Nature 2000 Aug 17, 406:747-752.
40. Sorlie T., Perou C.M., Tibshirani R., Aas T., Geisler S., Johnsen H., et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci U S A , 2001 Sep 11, 98:10869-10874.
41. Baselga J., Cortes J., Kim S.B., Im S.A., Hegg R., Im Y.H., et al. Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer. N Engl J Med 2012, 366:109-119.
42. Verma S., Miles D., Gianni L., Krop I.E., Welslau M., Baselga J., et al. Trastuzumab emtansine for HER2-positive advanced breast cancer. N Engl J Med 2012, 367:1783-1791.
43. Feeley L.P., Mulligan A.M., Pinnaduwage D., Bull S.B., Andrulis I.L. Distinguishing luminal breast cancer subtypes by Ki67, progesterone receptor or TP53 status provides prognostic information. Mod Pathol 2014, 27:554-561.
44. The National Comprehensive Cancer Network. National Comprehensive Cancer Network Clinical Practice Guidelines in Oncology. Breast cancer. Version 3.2014. Available at: http://www.nccn.org/professionals/physician_gls/pdf/breast.pdf [accessed 01.09.2014].
45. Slamon D.J., Clark G.M., Wong S.G., Levin W.J., Ullrich A., McGuire W.L. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 1987, 235:177-182.
46. Geyer C.E., Forster J., Lindquist D., Chan S., Romieu C.G., Pienkowski T., et al. Lapatinib plus capecitabine for HER2-positive advanced breast cancer. N Engl J Med 2006, 355:2733-2743.
47. Pierga J.Y., Hajage D., Bachelot T., Delaloge S., Brain E., Campone M., et al. High independent prognostic and predictive value of circulating tumor cells compared with serum tumor markers in a large prospective trial in first-line chemotherapy for metastatic breast cancer patients. Ann Oncol 2012, 23:618-624.
48. Lucci A., Hall C.S., Lodhi A.K., Bhattacharyya A., Anderson A.E., Xiao L., et al. Circulating tumour cells in non-metastatic breast cancer: a prospective study. Lancet Oncol 2012, 13:688-695.
49. Wallwiener M., Hartkopf A.D., Baccelli I., Riethdorf S., Schott S., Pantel K., et al. The prognostic impact of circulating tumor cells in subtypes of metastatic breast cancer. Breast Cancer Res Treat 2013, 137:503-510.
50. Weissenstein U., Schumann A., Reif M., Link S., Toffol-Schmidt U.D., Heusser P. Detection of circulating tumor cells in blood of metastatic breast cancer patients using a combination of cytokeratin and EpCAM antibodies. BMC Cancer 2012, 12:206.
51. Hartkopf A.D., Wagner P., Wallwiener D., Fehm T., Rothmund R. Changing levels of circulating tumor cells in monitoring chemotherapy response in patients with metastatic breast cancer. Anticancer Res 2011, 31:979-984.
52. Hayes D.F., Cristofanilli M., Budd G.T., Ellis M.J., Stopeck A., Miller M.C., et al. Circulating tumor cells at each follow-up time point during therapy of metastatic breast cancer patients predict progression-free and overall survival. Clin Cancer Res 2006, 12:4218-4224.
53. Cristofanilli M., Budd G.T., Ellis M.J., Stopeck A., Matera J., Miller M.C., et al. Circulating tumor cells, disease progression, and survival in metastatic breast cancer. N Engl J Med 2004, 351:781-791.
54. Cristofanilli M., Hayes D.F., Budd G.T., Ellis M.J., Stopeck A., Reuben J.M., et al. Circulating tumor cells: a novel prognostic factor for newly diagnosed metastatic breast cancer. J Clin Oncol 2005, 23:1420-1430.
55. Elston C.W., Ellis I.O. Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up. Histopathology 1991, 19:403-410.
56. Liu M.T., Huang W.T., Wang A.Y., Huang C.C., Huang C.Y., Chang T.H., et al. Prediction of outcome of patients with metastatic breast cancer: evaluation with prognostic factors and Nottingham prognostic index. Support Care Cancer 2010, 18:1553-1564.
57. Poikonen P., Sjostrom J., Amini R.M., Villman K., Ahlgren J., Blomqvist C. Cyclin A as a marker for prognosis and chemotherapy response in advanced breast cancer. Br J Cancer 2005, 93:515-519.
58. Tazhibi M., Fayaz M., Mokarian F. Detection of prognostic factors in metastatic breast cancer. J Res Med Sci 2013, 18:283-290.
59. de Azambuja E., Cardoso F., de Castro G., Colozza M., Mano M.S., Durbecq V., et al. Ki-67 as prognostic marker in early breast cancer: a meta-analysis of published studies involving 12,155 patients. Br J Cancer 2007, 96:1504-1513.
60. Anderson H., Hills M., Zabaglo L., A'hern R., Leary A.F., Haynes B.P., et al. Relationship between estrogen receptor, progesterone receptor, HER-2 and Ki67 expression and efficacy of aromatase inhibitors in advanced breast cancer. Ann Oncol 2011, 22:1770-1776.
61. Delpech Y., Wu Y., Hess K.R., Hsu L., Ayers M., Natowicz R., et al. Ki67 expression in the primary tumor predicts for clinical benefit and time to progression on first-line endocrine therapy in estrogen receptor-positive metastatic breast cancer. Breast Cancer Res Treat 2012, 135:619-627.
62. Falato C., Lorent J., Tani E., Karlsson E., Wright P.K., Bergh J., et al. Ki67 measured in metastatic tissue and prognosis in patients with advanced breast cancer. Breast Cancer Res Treat 2014, 147:407-414.
63. Ellis M.J., Perou C.M. The genomic landscape of breast cancer as a therapeutic roadmap. Cancer Discov 2013, 3:27-34.
64. Li S., Shen D., Shao J., Crowder R., Liu W., Prat A., et al. Endocrine-therapy-resistant ESR1 variants revealed by genomic characterization of breast-cancer-derived xenografts. Cell Rep 2013, 4:1116-1130.